LENZ Therapeutics LENZ
NASDAQ LENZ
$3.22 +0.03 (+0.94%)
As of: Oct 21, 2026 · 3:59 PM EDT

LENZ Therapeutics (LENZ) Cash from Restructuring (2024)

Updated

LENZ Therapeutics (LENZ) posted Cash from Restructuring of -$4.77 million for Q2 2024.

Analysis

LENZ Therapeutics (LENZ) Cash from Restructuring (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 LENZ Therapeutics 101.65 Mn -871.25 Mn 5.21 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 -4.77 Mn
Mar 31, 2024 4.82 Mn
API Access

LENZ Therapeutics Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=LENZ&period=max&api_key=YOUR_API_KEY